Darville T: Pelvic inflammatory disease: identifying research gaps—proceedings of a workshop sponsored by the De-partment of Health and Human Services/National Institutes of Health/National Institute of Allergy and Infectious Diseas-es, November 3-4. 2013, OCT:761-7.

Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL: Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol. 2012, 120:37-43.

Burnett AM, Anderson CP, Zwank MD: Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med. 2012, 30:1114-7.

Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL: A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease. Clin Infect Dis. 2021, 8:1181-1189.

Ness RB, Kip KE, Hillier SL, et al.: A cluster analysis of bacte-rial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol. 2005, 162:585-90.

Gray RH, Kigozi G, Serwadda D, et al.: The effects of male circumcision on female partners’ genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol. 2009, 200:1-7.

Oakeshott P, Aghaizu A, Hay P, et al.: Is Mycoplasma genitali-um in women the “New Chlamydia?” A community-based prospective cohort study. Clin Infect Dis. 2010, 51:1160-6.

CDC. Sexually Transmitted Diseases Treatment Guidelines. Atlanta, GA: Department of Health and Human Services. Ac-cessed: 15 Dec 2024: http://www.cdc.gov/mmwr .

Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL: Sub clinical pelvic inflammatory disease and infertility. Ob-stet Gynecol. 2012, 120:37-43.

Simms I, Stephenson JM, Mallinson H, et al.: Risk factors associated with pelvic inflammatory disease. Sex Transm In-fect. 2006, 82:452-457. 10.1136/sti.2005.019539.

Workowski KA, Bolan GA Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guide-lines.(published correction appears in MMWR Recomm Rep. 2015;64(RR-03):1-137.

Manhart, L. E., Broad, J. M., Golden, M. R. (2007: Mycoplas-ma genitalium: Should We Treat and Screen?. Current Opin-ion in Infectious Diseases. 20:47-52.

Onderdonk, A. B., Delaney, M. L., Fichorova, R. N. (2016: The Human Microbiome during Bacterial Vaginosis.. Clinical Mi-crobiology Reviews. 29:223-238.

Haggerty, C. L., & Ness, R. B. Diagnosis and Treatment of Pelvic Inflammatory Disease.. Women's Health (London. 2006;2:59-70.

Mitchell CM, Anyalechi G, Cohen CR, Haggerty CL, Manhart LE, Hillier SL: Etiology and diagnosis of pelvic in flammatory disease: looking beyond gonorrhea and chlamydia. J Infect Dis. 2021, 224:29-35.

American College of Obstetrics and Gynecology. Frequently asked questions. Accessed: 15 Dec 2024: https://www.acog.org/womens-health/ faqs/pelvic-inflammatory-disease..

Mayo Clinic. Pelvic inflammatory disease. Accessed: 15 Dec 2024: https://www.mayoclinic.org/diseases-conditions/pelvic-inflammatory-disease/symptoms-causes/syc-20352594

Haggerty CL, Hillier SL, Bass DC, Ness RB; PID Evaluation and Clinical Health study investigators: Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin In-fect Dis. 2004, 39:990-5.

Hebb JK, Cohen CR, Astete SG, Bukusi EA, Totten PA: Detec-tion of novel organisms associated with salpingitis, by use of 16S rDNA polymerase chain reaction. J Infect Dis. 2004, 190:2109-20.

Turpin R, Tuddenham S, Klebanoff M, Ghanem K, Brotman R: Bacterial vaginosis and behavioural factors as sociated with the incident pelvic inflammatory disease in the longitu-dinal study of vaginal flora. J Infect Dis. 2021, 224:137-44.

Haggerty CL, Ness RB, Totten PA, et al.: The presence and concentrations of select bacterial vaginosis-associated bacte-ria are associated with an increased risk of pelvic inflamma-tory disease. Sex Transm Dis. 2020, 47:344-6.

Lis R, Rowhani-Rahbar A, Manhart LE: Mycoplasma genitali-um infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis. 2015, 61:418-26.

Brunham RC, Gottlieb SL, Paavonen J: Pelvic inflammatory disease. N Engl J Med. 2015, 372:2039-2048.

Parasar P, Ozcan P, Terry KL: Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017, 6:34-41.

Kitaya K, Takeuchi T, Mizuta S, et al.: Endometritis: new time, new concepts. Fertil Steril. 2018, 110:344-350.

Treatment and prevention of kidney stones: an update.. Accessed: 2024 Dec 15: https://www.aafp.org/afp/2011/1201/p1234.html .

Sweet RL: Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2011, 561909:10.

Petrina MAB, Cosentino LA, Wiesenfeld HC, Darville T, Hillier SL: Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histolog-ical endometritis to antimicrobial agents. Anaerobe. 2019, 56:61-5.

Haggerty CL, Totten PA, Tang G, et al.: Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect. 2016, 92:441-6.

Ness RB, Randall H, Richter HE, et a;: Pelvic Inflammatory Disease Evaluation and Clinical Health Study Investigators. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an epi-sode of pelvic inflammatory disease.. Am J Public Health. 2004, 94:1327-9.

McGregor JA, Crombleholme WR, Newton E, Sweet RL, Tuomala R, Gibbs RS.: Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis.. Obstet Gynecol. 1994, 83:998-1004.

Bevan CD, Ridgway GL, Rothermel CD.: Efficacy and safety of azithromycin as monotherapy or combined with metronida-zole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res. 2003, 31:45-54.

Ness RB, Soper DE, Holley RL, et al.: Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial.. Am J Obstet Gynecol. 2002, 186:929-37.

Pelvic inflammatory disease (PID) - STI treatment guidelines.. (2021). https://www.cdc.gov/std/treatment-guidelines/pid.htm .

Hosenfeld CB, Workowski KA, Berman S, et al.: Repeat infec-tion with Chlamydia and gonorrhea among females: a sys-tematic review of the literature. Sex Transm Dis. 2009, 36:478-89.

Golden MR, Whittington WL, Handsfield HH: et Effect of expedited treatment of sex partners on recurrent or persis-tent gonorrhea or chlamydial infection. N Engl J Med. 2005, 352:676-85.

Park MA, Koch CA, Klemawesch P, Joshi A, Li JT: Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol. 2010, 153:268-73.

Ahmed KA, Fox SJ, Frigas E, Park MA: Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. Int Arch Allergy Immunol. 2012:405-10.

Macy E, Vyles D: Who needs penicillin allergy testing?. An Allergy Asthma Immunol. 2018, 121:523-9.

Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ: Antibiotic allergy. Lancet. 2019, 393:183-98. 10.1016/S0140-6736.

Jatlaoui TC, Riley HEM, Curtis KM: The safety of intrauterine devices among young women: a systematic review. Contra-ception. 2017, 95:17-39.

Tepper NK, Steenland MW, Gaffield ME, Marchbanks PA, Curtis KM: Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception. 2013, 87:655-60.